Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
NCT #
NCT05512377
Condition(s)
Bile Duct Cancer (Cholangiocarcinoma), Lung Cancer (NSCLC), Pancreatic Cancer, Urothelial Cancer
Molecular Target(s)
MDM2
Drug Classification(s)
n/a
Agents(s)
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
Phase(s)
II
Mechanism of Action
BI 907828 is a so-called MDM2 inhibitor
Purpose
n/a
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.